Cargando…
Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes
Anti-β2-glycoprotein I/HLA-DR (anti-β2GPI/HLA-DR) antibody has been reported to be associated with antiphospholipid syndrome and recurrent pregnancy loss (RPL). We conducted a prospective multicenter cross-sectional study aimed at evaluating whether the anti-β2GPI/HLA-DR antibody is associated with...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342169/ https://www.ncbi.nlm.nih.gov/pubmed/37446134 http://dx.doi.org/10.3390/ijms241310958 |
_version_ | 1785072438300639232 |
---|---|
author | Tanimura, Kenji Saito, Shigeru Tsuda, Sayaka Ono, Yosuke Ota, Hajime Wada, Shinichiro Deguchi, Masashi Nakatsuka, Mikiya Nagamatsu, Takeshi Fujii, Tomoyuki Kobashi, Gen Arase, Hisashi Yamada, Hideto |
author_facet | Tanimura, Kenji Saito, Shigeru Tsuda, Sayaka Ono, Yosuke Ota, Hajime Wada, Shinichiro Deguchi, Masashi Nakatsuka, Mikiya Nagamatsu, Takeshi Fujii, Tomoyuki Kobashi, Gen Arase, Hisashi Yamada, Hideto |
author_sort | Tanimura, Kenji |
collection | PubMed |
description | Anti-β2-glycoprotein I/HLA-DR (anti-β2GPI/HLA-DR) antibody has been reported to be associated with antiphospholipid syndrome and recurrent pregnancy loss (RPL). We conducted a prospective multicenter cross-sectional study aimed at evaluating whether the anti-β2GPI/HLA-DR antibody is associated with adverse obstetric outcomes and RPL. From 2019 to 2021, serum anti-β2GPI/HLA-DR antibody levels (normal, <73.3 U) were measured in 462 women with RPL, 124 with fetal growth restriction (FGR), 138 with hypertensive disorders of pregnancy (HDP), 71 with preterm delivery before 34 gestational weeks (preterm delivery (PD) ≤ 34 GWs), and 488 control women who experienced normal delivery, by flow cytometry analysis. The adjusted odds ratios (aORs) of anti-β2GPI/HLA-DR antibody positivity for adverse obstetric outcomes and RPL were evaluated on the basis of comparisons between the control and each patient group, using multivariable logistic regression analysis. The following were the positivity rates for the anti-β2GPI/HLA-DR antibody in the patient and control groups: RPL, 16.9%; FGR, 15.3%; HDP, 17.4%; PD ≤ 34 GWs, 11.3%; and the control, 5.5%. It was demonstrated that anti-β2GPI/HLA-DR antibody positivity was a significant risk factor for RPL (aOR, 3.3 [95% confidence interval {CI} 1.9–5.6], p < 0.001), FGR (2.7 [1.3–5.3], p < 0.01), and HDP (2.7 [1.4–5.3], p < 0.01) although not for PD ≤ 34 GWs. For the first time, our study demonstrated that the anti-β2GPI/HLA-DR antibody is involved in the pathophysiology underlying FGR and HDP, as well as RPL. |
format | Online Article Text |
id | pubmed-10342169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103421692023-07-14 Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes Tanimura, Kenji Saito, Shigeru Tsuda, Sayaka Ono, Yosuke Ota, Hajime Wada, Shinichiro Deguchi, Masashi Nakatsuka, Mikiya Nagamatsu, Takeshi Fujii, Tomoyuki Kobashi, Gen Arase, Hisashi Yamada, Hideto Int J Mol Sci Article Anti-β2-glycoprotein I/HLA-DR (anti-β2GPI/HLA-DR) antibody has been reported to be associated with antiphospholipid syndrome and recurrent pregnancy loss (RPL). We conducted a prospective multicenter cross-sectional study aimed at evaluating whether the anti-β2GPI/HLA-DR antibody is associated with adverse obstetric outcomes and RPL. From 2019 to 2021, serum anti-β2GPI/HLA-DR antibody levels (normal, <73.3 U) were measured in 462 women with RPL, 124 with fetal growth restriction (FGR), 138 with hypertensive disorders of pregnancy (HDP), 71 with preterm delivery before 34 gestational weeks (preterm delivery (PD) ≤ 34 GWs), and 488 control women who experienced normal delivery, by flow cytometry analysis. The adjusted odds ratios (aORs) of anti-β2GPI/HLA-DR antibody positivity for adverse obstetric outcomes and RPL were evaluated on the basis of comparisons between the control and each patient group, using multivariable logistic regression analysis. The following were the positivity rates for the anti-β2GPI/HLA-DR antibody in the patient and control groups: RPL, 16.9%; FGR, 15.3%; HDP, 17.4%; PD ≤ 34 GWs, 11.3%; and the control, 5.5%. It was demonstrated that anti-β2GPI/HLA-DR antibody positivity was a significant risk factor for RPL (aOR, 3.3 [95% confidence interval {CI} 1.9–5.6], p < 0.001), FGR (2.7 [1.3–5.3], p < 0.01), and HDP (2.7 [1.4–5.3], p < 0.01) although not for PD ≤ 34 GWs. For the first time, our study demonstrated that the anti-β2GPI/HLA-DR antibody is involved in the pathophysiology underlying FGR and HDP, as well as RPL. MDPI 2023-06-30 /pmc/articles/PMC10342169/ /pubmed/37446134 http://dx.doi.org/10.3390/ijms241310958 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tanimura, Kenji Saito, Shigeru Tsuda, Sayaka Ono, Yosuke Ota, Hajime Wada, Shinichiro Deguchi, Masashi Nakatsuka, Mikiya Nagamatsu, Takeshi Fujii, Tomoyuki Kobashi, Gen Arase, Hisashi Yamada, Hideto Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes |
title | Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes |
title_full | Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes |
title_fullStr | Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes |
title_full_unstemmed | Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes |
title_short | Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes |
title_sort | anti-β2-glycoprotein i/hla-dr antibody and adverse obstetric outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342169/ https://www.ncbi.nlm.nih.gov/pubmed/37446134 http://dx.doi.org/10.3390/ijms241310958 |
work_keys_str_mv | AT tanimurakenji antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT saitoshigeru antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT tsudasayaka antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT onoyosuke antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT otahajime antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT wadashinichiro antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT deguchimasashi antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT nakatsukamikiya antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT nagamatsutakeshi antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT fujiitomoyuki antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT kobashigen antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT arasehisashi antib2glycoproteinihladrantibodyandadverseobstetricoutcomes AT yamadahideto antib2glycoproteinihladrantibodyandadverseobstetricoutcomes |